Deutsche Bank
ABCL icon

Deutsche Bank’s AbCellera Biologics ABCL Stock Holding History

Deutsche Bank’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-194,032
Closed -$1.25M – 3694
2023
Q2 		$1.25M Sell
194,032
-109,438
-36% -$747K ﹤0.01% 1862
2023
Q1 		$2.29M Buy
303,470
+84,850
+39% +$770K ﹤0.01% 1612
2022
Q4 		$2.21M Buy
218,620
+24,984
+13% +$289K ﹤0.01% 1603
2022
Q3 		$1.92M Buy
193,636
+3,920
+2% +$43K ﹤0.01% 1646
2022
Q2 		$2.02M Buy
189,716
+79,610
+72% +$674K ﹤0.01% 1746
2022
Q1 		$1.07M Buy
+110,106
New +$1.04M ﹤0.01% 2297
2021
Q4 		– Sell
-6,888
Closed -$138K – 4232
2021
Q3 		$138K Buy
+6,888
New +$122K ﹤0.01% 3748
2021
Q2 		– Sell
-2,395
Closed -$81K – 4576
2021
Q1 		$81K Buy
+2,395
New +$95.4K ﹤0.01% 4085

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Deutsche Bank's ABCL Position: Q3 2023 in Review

Deutsche Bank sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 194,032 shares — an estimated $1.25M sold.

Deutsche Bank first reported a position in ABCL in Q1 2021 and held it in 8 quarters. The position peaked at $2.29M in Q1 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Deutsche Bank reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Deutsche Bank sold 194,032 AbCellera Biologics shares in Q3 2023, an estimated $1.25M.
  • Deutsche Bank first reported a position in AbCellera Biologics in Q1 2021 and held it in 8 quarters.
  • Deutsche Bank's AbCellera Biologics position peaked at $2.29M in Q1 2023.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Deutsche Bank's 13F filing for Q3 2023, filed 9 Nov 2023.